Finerenone in IgA nephropathy: real-world 12-month propensity-matched cohort demonstrating proteinuria reduction, eGFR preservation, and safety profile

Objective To evaluate the efficacy and safety of finerenone in patients with IgA nephropathy (IgAN).Methods This retrospective study included 105 patients with IgAN (35 in the finerenone group, 70 in the control group) from January 2022 to February 2025. The finerenone group received conventional th...

Descripció completa

Dades bibliogràfiques

Autors principals:	Wei Zhang, Jing-ting Yu, Bo Lin, Xiaogang Shen, Maosheng Chen, Yi-dong Zhou, Yu-jia Zhang, Cheng-cong Zhuo, Zhi-liang Jiang, Bin Zhu
Format:	Artigo
Idioma:	Inglês
Publicat:	Taylor & Francis Group 2026-12-01
Col·lecció:	Renal Failure
Matèries:	IgA nephropathy finerenone non-steroidal mineralocorticoid receptor antagonist (MRA) proteinuria eGFR decline real-world evidence
Accés en línia:	https://www.tandfonline.com/doi/10.1080/0886022X.2026.2644719
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!